References
- King H, Aubert R, Herman W. Global burden of diabetes, 1995–2025. Diabetes Care 1998;21: 1414–31
- McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000;12(Suppl 4):6–11
- Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61
- Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidaemia, diabetes and depression in men with erectile dysfunction. J Urol 2004;171:2341–5
- Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multination men’s attitudes to life events and sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20:607–17
- Koppiker N, Boolell M, Price D. Recent advances in the treatment of erectile dysfunction in patients with diabetes mellitus. Endocr Pract 2003;9:52–63
- Blonde L, Korenman SG, Siegal RL, Orazem J. Sildenafil citrate for treatment of erectile dysfunction is similarly effective in men with type 1 or type 2 diabetes mellitus. Diabetes 2000;49\(Suppl 1):A88, abstract 354P
- Carter L, Abney TO, Lapp DF. Biosynthesis and metabolism of carnitine. J Child Neurol 1995;10(Suppl 2):3–7
- Ferrari R, Anand I. Utilization of propionyl-L-carnitine for the treatment of heart failure. In: De Jong JW, Ferrari R, eds. The Carnitine System. A New Therapeutical Approach to Cardiovascular Diseases. Dordrecht: Kluwer Academic Publishers, 1995:323–35
- De Grandis D, Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy: A long-term, randomised, double-blind, placebo-controlled study. Drugs R D 2002;3:223–31
- Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, Cooke JP, Olin JW. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001;110:616–22
- Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-L-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie’s disease. BJU Int 2002;89:895–900
- Cippola M, Nicoloff A, Rebello T, Amato A, Porter J. Propionyl-L-carnitine dilates subcutaneous arteries through an endothelium-dependent mechanism. J Vasc Surg 1999;29:1097–13
- Corsico N, Arrigoni-Martelli E. Effects of propionyl-L-carnitine on experimental models of peripheral arteriopathy in the rat. In: De Jong JW, Ferrari R eds. The carnitine system: a new therapeutical approach to cardiovascular diseases. Dordrecht: Kluwer Academic Publishers. Chapter 26, pp365–382,1995
- National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039–57
- Rosen RC, Cappelleri JC, Gendrano N 3rd. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res, 2002;14: 226–44
- Dey J, Shepherd MD. Evaluation and treatment of erectile dysfunction in men with diabetes mellitus. Mayo Clin Proc 2002;77:276–82
- Price DE, Gingell JC, Gepi-Atte S, Wareham K, Yates P, Boolell M. Sildenafil: study of a novel oral treatment for erectile dysfunction in men. Diabet Med 1998;15:821–5
- Langtry HD, Markham A. Sildenafil, a review of its use in erectile dysfunction. Drugs 1999;57:967–89
- Korenman SG, Siegal RL, Stecher VJ, Orazem J. Efficacy of sildenafil citrate in men with erectile dysfunction and diabetes mellitus: effect of patient age and disease duration. Presented at 83rd Annual Meeting of the Endocrine Society, Denver, CO, USA, June 20–23,2001
- Herrera MD, Bueno R, Sotomayor De MA, Perez-Guerrero C, Vazquez CM, Marhuenda E. Endothelium-dependent vasorelaxation induced by L-carnitine in isolated aorta from normotensive and hypertensive rats. J Pharm Pharmcol 2002;54:1423–7
- Bertelli A, Conte A, Ronca G, Segnini D, Yu G. Protective effect of propionylcarnitine against peroxidative damage to arterial endothelium membranes. Int J Tissue React 1991;13:41–3
- Guay AT, Blonde L, Siegal RL, Orazem J. Safety and tolerability of sildenafil citrate for the treatment of erectile dysfunction in men with type 1 and type 2 diabetes mellitus. Diabetes 2000;49\(Suppl 1):A90, abstract 363P
- De Rose AF, Giglio M, Traverso P, Lantieri P, Carmignani G. Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res, 2002;14:50–3
- Mydlo JH, Volpe MA, Macchia RJ. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol 2000;38:30–4